Produktinformation
- 1,2-Dihydro-2,7-Naphthyridin-1-One
Cabozantinib is a small molecule that is the first to target VEGFR-2, which is a receptor tyrosine kinase involved in the development of fibrosis. Cabozantinib inhibits the activity of VEGFR-2 by binding to its ATP-binding site and blocking the phosphorylation of downstream signaling pathways. Cabozantinib has been shown to have antifibrotic properties in both preclinical and clinical models. The drug candidate has been shown to reduce kidney fibrosis in animal models. The standard dose for cabozantinib was found to be 5 mg/kg, with a maximum tolerated dose of 20 mg/kg. In vitro studies have indicated that cabozantinib binds with high affinity to the ATP-binding pocket of VEGFR-2, exhibiting competitive inhibition against other kinases such as PDGFR-beta and cKit, as well as diaryliodonium (a specific inhibitor). Caboz
Chemische Eigenschaften
Technische Anfrage zu: 3D-SCA98850 2,7-Naphthyridin-1(2H)-one
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
